Related Experiment Video

Updated: Aug 21, 2026

Biochemical Titration of Glycogen In vitro
07:16

Biochemical Titration of Glycogen In vitro

Published on: November 24, 2013

[Glycogen storage disease type IX presenting as abdominal distention, hepatomegaly and hypoglycemia during infancy]

P Soler Palacín1, N Tomasa Wörner, J Sánchez de Toledo Sancho

  • 1Servicio de Pediatría, Hospital de la Vall d'Hebron, Barcelona, Spain. 34660psp@comb.es

Anales De Pediatria (Barcelona, Spain : 2003)
|November 9, 2004
PubMed

Insights

Glycogen storage diseases, like glycogenosis type IX, require prompt diagnosis in children with growth issues. Early intervention with a high-carbohydrate diet improved this patient's growth and clinical response.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Genetics

Background:

  • Glycogen storage diseases (GSDs) are rare but significant in pediatric practice.
  • Consider GSDs in children with poor growth, hepatomegaly, hypoglycemia, or hypotonia.
  • Early diagnosis is crucial for timely treatment and genetic counseling.

Observation:

  • A 10-month-old boy presented with growth retardation, abdominal distention, and hepatomegaly.
  • The patient was diagnosed with glycogenosis type IX, a specific GSD.
  • The diagnosis was confirmed by identifying a phosphorylase beta-kinase enzyme defect.

Findings:

  • Glycogenosis type IX was diagnosed in a 10-month-old boy.
  • Enzyme defect (phosphorylase beta-kinase) confirmed the diagnosis.
  • Enteral nutrition with a high-carbohydrate diet and continuous nasogastric feeding was initiated.

Implications:

  • Early diagnosis and intervention in GSDs can significantly improve patient outcomes.
  • Nutritional management, including specialized diets, is key to managing GSDs.
  • Understanding enzyme defects aids in diagnosing and managing rare metabolic disorders.

More Related Videos

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining09:42

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining

Published on: December 23, 2014

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination04:50

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination

Published on: February 8, 2022

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...